Addition Therapeutics
Cell & Gene Therapy
3open roles
$100Mlatest round · Venture round · Dec 2025 · 10 mo ago
1backers · SR One
62team · US Form 5500 (plan participants) · Dec 2025 · +3% in a year
Overview
We're on a mission to fulfill the promise of genetic medicine for all patients. At Addition, we are advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases in large and rare populations.
Funding and backers
Total raised
$100M
2 rounds on record
Latest round
$100M
Venture round · Dec 2025 · 10 mo ago
Team
62
US Form 5500 (plan participants) · Dec 2025 · +3% in a year
Hiring now
3
+1 posted in 30 days
Backers
1
SR One
The money's age
Fresh money
10 months since the last round · and hiring
Momentum
33/100
hiring for its size, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Dec 2025 | $100M | — | additiontx.com |
| Debt Financing | Dec 2025 | $28M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Addition Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Lawrence KongExecutive OfficerSEC Form D
Ronald ParkExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Carmine Therapeutics is pioneering a powerful new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs).
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
Instant Quantification of genetic modifications for Cell and Gene Therapies.
At Jaguar Gene Therapy, we believe in a world where patients and families won’t have to hear those words. Our mission is to accelerate…
Alia Therapeutics is a startup which is developing next-generation gene editing medicines to cure genetic diseases.
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
Jobs
$130k – $140k per year · In office · Contractor · 3+ years exp · Bachelor's Degree · South San Francisco
Benchling
Apply
$78k – $98k per year · Equity · In office · Full-Time · 1+ year exp · Bachelor's Degree · South San Francisco
Python
qPCR
Flow Cytometry
ELISA
Western Blot
Cell Culture
GraphPad Prism
Apply
$130k – $150k per year · In office · Contractor · 1+ year exp · PhD · South San Francisco
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$140k
Typical range
$98k – $150k
Open positions
3
3
Jobs
Junior
66.7%
Middle
33.3%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Junior | 2 | $124k | $98k – $150k |
| Middle | 1 | $140k | $140k |
Highest paying role
SRA / Scientist, Lipid Nanoparticle (LNP) Discovery - Contractor
$150k
Normalized to USD per year
Visa sponsorship
3 ▲ 200%
H-1B filings in 12 months
$118k
Median offered salary
3
Open roles in United States
Who they sponsor
Other biological scientists
2
Biochemists and biophysicists
1
In the register as Addition Therapeutics, Inc., South San Francisco, CA
Other sponsors in the same field
Vertex Pharmaceuticals 
Genscript 
Kite Pharma 
Alnylam
See 3 open roles Alert me
US Department of Labor · latest filing Jun 11, 2026 · Visa details by country
Growth
Hiring Momentum
50/100
Stable
Open positions
3
1 opened / 1 closed in 30 days
Median time-to-fill
57 days
faster than 24% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
57% ▼
Management
14% ▲
Industrial Engineering
14% ▼
Biotech
14% ▼
Activity Timeline
Added Benchling to stack
Oct 2026
Added Western Blot to stack
Oct 2026
Added qPCR to stack
Oct 2026
Added GraphPad Prism to stack
Oct 2026
Added Cell Culture to stack
Oct 2026
Added Flow Cytometry to stack
Oct 2026
Added ELISA to stack
Oct 2026
People
Lawrence Kong
Executive Officer
Ronald Park
Executive Officer, Director
Kathleen Collins
Director
Jayson Punwani
Director
Matthew Patterson
Director
Peter Bisgaard
Director
Jennifer Lee
Director
Laetitia Schwab
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Addition Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
8
Postings analysed
3
Stack modernity
56/100
Languages
Python
Sign in to see how your skills match this stack
Sign In
Full Addition Therapeutics tech stack
8 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SR OneVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Addition Therapeutics Presents Preclinical Proof-of-Concept Data at American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
Read more
Report
Addition Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
Read more
Report
Addition Therapeutics: One genomic safe site, many DNA insertions
Addition emerged from stealth today as the newest entrant in a small group of companies developing gene-writing therapeutics, differentiated by its retrotr...
Read more
Report
Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases
South San Francisco, CA; December 17, 2025 - Addition Therapeutics emerged from stealth today, announcing $100 million in financing to date and notable progress advancing its mission to fulfill the transformative promise of genomic medicine for people imp
Read more
Report
Addition Debuts With $100M to Advance One-Time Therapies for Rare, Chronic Diseases
Addition joins a growing list of launches this year, following in the footsteps of startups like Crystalys Therapeutics and Ollin Biosciences.
Read more
Report
Addition launches with an all-RNA, lipid nanoparticle-based gene therapy
Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene therapy platform. The system is based on research of retrotransposons by Kathleen Collins' laboratory at University of California, Be
Read more
Report
Addition emerges with $100M to make gene therapies for chronic and rare diseases
Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes can sidestep issues seen with traditional gene therapy technology.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
South San Francisco
South San Francisco
United States
HQ
Addition Therapeutics
3 open roles 7 posted in 90 days 67% engineering $129k Avg Salary
hires for Science & Research, Management
201 Haskins Way, Suite 300, South San Francisco, CA 94080